EE04851B1 - 4H-1-bensopüraan-4-ooni derivaatide kasutamine ravimi valmistamiseks silelihasrakkude proliferatsiooni inhibeerimiseks - Google Patents

4H-1-bensopüraan-4-ooni derivaatide kasutamine ravimi valmistamiseks silelihasrakkude proliferatsiooni inhibeerimiseks

Info

Publication number
EE04851B1
EE04851B1 EEP200100385A EEP200100385A EE04851B1 EE 04851 B1 EE04851 B1 EE 04851B1 EE P200100385 A EEP200100385 A EE P200100385A EE P200100385 A EEP200100385 A EE P200100385A EE 04851 B1 EE04851 B1 EE 04851B1
Authority
EE
Estonia
Prior art keywords
benzopyran
medicament
derivatives
manufacture
cell proliferation
Prior art date
Application number
EEP200100385A
Other languages
English (en)
Estonian (et)
Inventor
Campbell Patterson Winston
Ann Dumont Jennifer
Original Assignee
Aventis Pharmaceuticals Inc.
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc., Board Of Regents, The University Of Texas System filed Critical Aventis Pharmaceuticals Inc.
Publication of EE200100385A publication Critical patent/EE200100385A/xx
Publication of EE04851B1 publication Critical patent/EE04851B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200100385A 1999-02-01 2000-01-18 4H-1-bensopüraan-4-ooni derivaatide kasutamine ravimi valmistamiseks silelihasrakkude proliferatsiooni inhibeerimiseks EE04851B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24338099A 1999-02-01 1999-02-01
US09/468,665 US6399633B1 (en) 1999-02-01 1999-12-21 Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
PCT/US2000/001104 WO2000044362A2 (en) 1999-02-01 2000-01-18 The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation

Publications (2)

Publication Number Publication Date
EE200100385A EE200100385A (et) 2002-12-16
EE04851B1 true EE04851B1 (et) 2007-06-15

Family

ID=22918541

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100385A EE04851B1 (et) 1999-02-01 2000-01-18 4H-1-bensopüraan-4-ooni derivaatide kasutamine ravimi valmistamiseks silelihasrakkude proliferatsiooni inhibeerimiseks

Country Status (38)

Country Link
US (1) US6399633B1 (https=)
EP (1) EP1150746B1 (https=)
JP (1) JP4755759B2 (https=)
KR (1) KR100793047B1 (https=)
CN (1) CN1219556C (https=)
AP (1) AP1469A (https=)
AR (1) AR042569A1 (https=)
AT (1) ATE275428T1 (https=)
AU (1) AU777368B2 (https=)
BG (1) BG65151B1 (https=)
BR (1) BR0007911A (https=)
CA (1) CA2360668C (https=)
CR (1) CR6448A (https=)
CZ (1) CZ300395B6 (https=)
DE (1) DE60013555T2 (https=)
DK (1) DK1150746T3 (https=)
EA (1) EA004786B1 (https=)
EE (1) EE04851B1 (https=)
ES (1) ES2226792T3 (https=)
HK (1) HK1042445B (https=)
HR (1) HRP20010521A2 (https=)
HU (1) HU229263B1 (https=)
ID (1) ID30180A (https=)
IL (1) IL144668A (https=)
ME (1) MEP10508A (https=)
NO (1) NO330512B1 (https=)
NZ (1) NZ512822A (https=)
OA (1) OA11755A (https=)
PL (1) PL197693B1 (https=)
PT (1) PT1150746E (https=)
RS (1) RS50242B (https=)
SI (1) SI1150746T1 (https=)
SK (1) SK286747B6 (https=)
TR (1) TR200102223T2 (https=)
TW (1) TWI273907B (https=)
UA (1) UA73110C2 (https=)
WO (1) WO2000044362A2 (https=)
ZA (1) ZA200105596B (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102480D0 (en) * 2001-01-31 2001-03-14 Cyclacel Ltd Marker
AU2003234733B2 (en) * 2002-04-17 2009-01-29 Cytokinetics, Inc. Compounds, compositions, and methods
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
WO2004002226A1 (en) * 2002-06-28 2004-01-08 Baylor College Of Medicine Modulators of cdk9 as a therapeutic target in cardiac hypertrophy
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP1660186B1 (en) 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
EP1893647A2 (en) 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
WO2007010342A1 (en) * 2005-07-15 2007-01-25 Sahajanand Biotech Private Limited Implantable medical devices comprising a flavonoid or derivative thereof for prevention of restenosis
JP2008255008A (ja) * 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ 滑膜細胞増殖抑制剤
CA2617213C (en) * 2005-07-29 2014-01-28 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
ES2439994T3 (es) 2006-08-28 2014-01-27 Kyowa Hakko Kirin Co., Ltd. Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
WO2008092231A1 (en) 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
KR101629356B1 (ko) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 퀴나졸리논 유도체의 제조방법
AU2010204106B2 (en) 2009-01-08 2014-05-08 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
NZ755378A (en) 2009-03-18 2022-07-29 Resverlogix Corp Novel quinazolinones and related compounds for use as anti-inflammatory agents
KR20190091564A (ko) 2009-04-22 2019-08-06 리스버로직스 코퍼레이션 신규한 소염제
WO2012007327A1 (en) 2010-07-12 2012-01-19 Dkfz Deutsches Krebsforschungszentrum Wogonin for the prevention and therapy of cardiac hypertrophy
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
RU2640115C2 (ru) 2011-11-01 2017-12-26 Ресверлоджикс Корп. Фармацевтические композиции замещенных хиназолинонов
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
SG11201509982UA (https=) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
KR102313341B1 (ko) 2013-08-26 2021-10-18 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
DK3154583T3 (da) 2014-06-04 2021-03-22 Biontech Res And Development Inc Humane monoklonale antistoffer mod gangliosid gd2
PL3333191T3 (pl) 2014-12-11 2021-05-04 Pierre Fabre Médicament Przeciwciała przeciwko c10orf54 i ich zastosowania
MX2017011194A (es) 2015-03-03 2018-04-10 Kymab Ltd Anticuerpos, usos y métodos.
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
US9901574B2 (en) 2015-04-20 2018-02-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
ES2739749T3 (es) 2015-05-18 2020-02-03 Tolero Pharmaceuticals Inc Profármacos de alvocidib que tienen biodisponibilidad aumentada
MX2018001289A (es) 2015-08-03 2018-04-30 Tolero Pharmaceuticals Inc Terapias de combinacion para el tratamiento del cancer.
CN114470194A (zh) 2015-12-02 2022-05-13 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
KR102815803B1 (ko) 2015-12-02 2025-06-05 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
CN109803684B (zh) 2016-08-23 2022-08-23 卫材 R&D 管理有限公司 用于治疗肝细胞癌的组合疗法
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US11083722B2 (en) 2017-03-16 2021-08-10 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
US12215151B2 (en) 2017-05-31 2025-02-04 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
KR102767692B1 (ko) 2018-07-20 2025-02-17 피에르 파브르 메디카먼트 Vista의 수용체
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
CN113559244B (zh) * 2021-08-02 2023-12-26 华中科技大学同济医学院附属协和医院 Ctrp13脂肪因子的新用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (https=) * 1986-04-11 1989-02-04 Hoechst India
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US5908934A (en) 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.

Also Published As

Publication number Publication date
ZA200105596B (en) 2002-10-07
JP4755759B2 (ja) 2011-08-24
EA200100742A1 (ru) 2001-12-24
WO2000044362A2 (en) 2000-08-03
TR200102223T2 (tr) 2004-12-21
CN1219556C (zh) 2005-09-21
AP1469A (en) 2005-09-26
DK1150746T3 (da) 2005-01-10
EA004786B1 (ru) 2004-08-26
AP2001002218A0 (en) 2001-09-30
CZ20012804A3 (cs) 2002-08-14
BG65151B1 (bg) 2007-04-30
UA73110C2 (en) 2005-06-15
PL197693B1 (pl) 2008-04-30
CN1338958A (zh) 2002-03-06
OA11755A (en) 2005-07-19
YU54401A (sh) 2004-05-12
MEP10508A (en) 2010-06-10
ID30180A (id) 2001-11-08
HRP20010521A2 (en) 2002-08-31
SI1150746T1 (en) 2005-02-28
AU3209800A (en) 2000-08-18
SK10862001A3 (sk) 2002-07-02
PT1150746E (pt) 2004-12-31
IL144668A0 (en) 2002-05-23
NO20013335L (no) 2001-09-25
BR0007911A (pt) 2001-10-16
ES2226792T3 (es) 2005-04-01
CR6448A (es) 2004-03-17
HK1042445A1 (en) 2002-08-16
KR100793047B1 (ko) 2008-01-10
AR042569A1 (es) 2005-06-29
JP2002535356A (ja) 2002-10-22
EE200100385A (et) 2002-12-16
ATE275428T1 (de) 2004-09-15
TWI273907B (en) 2007-02-21
CA2360668A1 (en) 2000-08-03
CZ300395B6 (cs) 2009-05-06
DE60013555D1 (de) 2004-10-14
HK1042445B (zh) 2006-01-13
EP1150746B1 (en) 2004-09-08
HUP0200804A3 (en) 2004-03-29
IL144668A (en) 2005-06-19
HU229263B1 (en) 2013-10-28
US6399633B1 (en) 2002-06-04
CA2360668C (en) 2009-03-17
KR20010093309A (ko) 2001-10-27
AU777368B2 (en) 2004-10-14
NO330512B1 (no) 2011-05-09
PL350735A1 (en) 2003-01-27
SK286747B6 (sk) 2009-04-06
WO2000044362A3 (en) 2001-04-05
NO20013335D0 (no) 2001-07-05
BG105751A (en) 2002-02-28
NZ512822A (en) 2005-01-28
RS50242B (sr) 2009-07-15
HUP0200804A2 (hu) 2002-12-28
DE60013555T2 (de) 2005-09-29
EP1150746A2 (en) 2001-11-07

Similar Documents

Publication Publication Date Title
EE04851B1 (et) 4H-1-bensopüraan-4-ooni derivaatide kasutamine ravimi valmistamiseks silelihasrakkude proliferatsiooni inhibeerimiseks
NO20021400D0 (no) Terapeutiske konazolinderivater
NO2013004I2 (no) Axitinib, valgfritt i form av et farmasøytisk aksentabelt salt
NO20022970D0 (no) Hydrogel-drevet medikamentdoseringsform
ATE258928T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
DE60040876D1 (de) Medikamentenzuführeinrichtung
EE04528B1 (et) Teraapias kasutatavad spirofuropridiinide aralklamiinid
DK1204410T3 (da) Farmaceutisk doseringsform med flere komponenter
ATE259796T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
EE200200656A (et) Ravis kasutatavad tropaani derivaadid
PT1296974E (pt) Derivados 2-cianopirrolidina e sua utilização como medicamentos
FI991485L (fi) Uusi farmaseuttinen koostumus
IS6343A (is) Fjölliðutöflukjarni með beinsláttu
NO20022645D0 (no) Farmasöytisk superdisintegrerende stoff
PT1070708E (pt) Derivados de triazol
EE03851B1 (et) Amiinide kasutamine kasvajarakkude paljunemise takistamiseks mõeldud ravimite tootmiseks
DK1176982T3 (da) Prucaloprid oral opløsning
GB9911238D0 (en) Therapeutic use
SK2625U (sk) Hra
ATA212499A (de) Spieltisch
DK199900178U3 (da) Tabletdeler
NO994697D0 (no) Prevensjonspille
NO992174D0 (no) S°ppelposefesteanordning
IS5004A (is) Ökklaliður
NO995276D0 (no) Behandlingsbenk

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20140118